SBIR-STTR Award

Boron neutron capture therapy (BNCT) optimization requires knowledge of tumor-boron uptake and elimination kinetics and concentrations. At present, this knowledge is obtained through invasive methods. Through a non-invasive method, multiple data points can be obtained over time without disturbing the biological environment. Initial studies have shown that magnetic resonance imaging (MRI) can be used as a non-invasive tool to determine boron concentration as a function of time and location. We will develop a new non-invasive technique using boron MRI to improve the researcher's ability to conduct boron pharmacokinctic studies.Awardee's statement of the potential commercial applications of the research:There are great potential commercial applications for a non-invasive tool to perform boron pharmacokinetic research within the BNCT research area. This research, presently involves over 25 countries and is of international concern in the search for cancer treatments.National Institute of Neurological Disorders and Stroke (NINDS)

We will promote the validation of Boron Neutron Capture Therapy (BNCT) an experimental brain tumor treatment, by providing boron concentration and distribution In the human brain for the target boron compound. Effective BNCT treatment requires the presence of (1) a nontoxic boron compound attaining a differential concentration between normal and tumor tissue, (2) an epithermal neutron source, and (3) knowledge of boron quantity, concentration and localization in the tumor before flooding the area with neutrons. Phase I demonstrated that Magnetic Resonance Imaging (MRI) can be used as a noninvasive imaging tool for BNCT. The principal Phase 11 research aims are to develop (I) an integrated coil assembly with two I IB coils for human and canine studies, (2) faster pulse sequences for improved scan efficiency, (3) efficient analysis and display software, and (4) to perform animal and human studies for final verification. The methodology employed to achieve these research aims will be the prototype development of MRI hardware and imaging analysis and reconstruction software. Analysis software will be UNIX based and will be integrated with reconstruction software. The technological innovation and commercial application resulting from this research will be add-on hardware and software to existing MRI equipment.Awardee's statement of the potential commercial applications of the research: Potential commercial applications include a noninvasive tool to perform boron pharmacokinetic research within the BNC r area. Potential users include universities and research centers with an interest in boron or BNCT. Eventually, the product will be marketed to cancer clinics and hospitals.National Institute of Neurological Disorders and Stroke (NINDS)